Maymetsi

Metformin Hydrochloride and Sitagliptin, the active ingredient in Maymetsi, is a Biguanide and DPP‑4 inhibitor presented as a tablet for oral use. It treats type 2 diabetes mellitus in adult patients by improving blood glucose control through multiple mechanisms that lower hepatic glucose output and increase insulin secretion.

GNH USA supplies Maymetsi as a licensed, GDP-compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide. The company adheres to stringent quality standards and provides reliable logistics for global distribution efficiently.

Maymetsi, containing metformin and sitagliptin, is indicated for management of type 2 diabetes mellitus, a disorder of glucose regulation. - Type 2 diabetes mellitus: improves glycemic control as monotherapy when metformin alone is insufficient. - Type 2 diabetes mellitus: used in combination with other antidiabetic agents such as insulin or sulfonylureas. - Type 2 diabetes mellitus: serves as adjunct to diet and exercise to achieve target HbA1c levels. - Type 2 diabetes mellitus: appropriate for patients requiring both hepatic glucose reduction and incretin‑based insulin secretion enhancement.

Common Side Effects: - Nausea: mild to moderate feeling of sickness. - Diarrhea: loose stools, often transient. - Headache: mild cranial discomfort. - Upper respiratory tract infection: symptoms such as sore throat or nasal congestion.

Serious or Rare Side Effects: - Lactic acidosis: rare but potentially fatal metabolic disturbance. - Pancreatitis: inflammation of the pancreas presenting with abdominal pain. - Severe hypersensitivity reactions: including skin rash, angioedema, or anaphylaxis.

Maymetsi should be used with careful clinical assessment and monitoring. - Renal function: assess creatinine clearance before initiating and monitor periodically. - Hepatic function: evaluate liver enzymes as metformin is contraindicated in severe hepatic disease. - Lactic acidosis risk: avoid in patients with severe renal impairment or acute heart failure. - Hypoglycemia risk: monitor closely when combined with insulin or sulfonylureas. - Pregnancy and lactation: use only if potential benefit justifies potential risk to fetus or infant. - Store at ambient temperature: keep below 25°C in original packaging, protect from moisture and light.

Maymetsi may interact with several medicines; clinicians should review patient medication lists. Major Interactions (Avoid): - Insulin or sulfonylureas: may cause severe hypoglycemia. - Iodinated contrast agents: increase risk of metformin-associated lactic acidosis. - Cimetidine: can raise metformin plasma concentrations.

Moderate Interactions (Monitor Closely): - ACE inhibitors or ARBs: monitor renal function and potassium levels. - Diuretics: may affect fluid balance and renal clearance. - Rifampin: may reduce sitagliptin exposure, requiring efficacy assessment.